Adage Capital Partners Gp, L.L.C. Avidity Biosciences, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.6 Billion
- Q3 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,079,374 shares of RNA stock, worth $98 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
3,079,374
Previous 3,396,982
9.35%
Holding current value
$98 Million
Previous $139 Million
1.92%
% of portfolio
0.26%
Previous 0.27%
Shares
8 transactions
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$338 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$294 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$274 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$259 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$224 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.66B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...